Form 4: Adverum Biotechnologies CFO's Stock Options Repriced Following Reverse Stock Split

Adverum Biotechnologies, Inc.'s Chief Financial Officer, Linda M. Rubinstein, had her stock options amended and repriced to a lower exercise price following the company's 1-for-10 reverse stock split.

Summary

• Linda M. Rubinstein, Chief Financial Officer of Adverum Biotechnologies, Inc. (ADVM), reported changes in her beneficial ownership of derivative securities via a Form 4 filing.
• The changes are a result of amendments to outstanding stock options, which involved the deemed cancellation of 'old' options and the grant of 'replacement' options.
• These amendments occurred on June 17, 2025, in connection with a 1-for-10 reverse stock split effected by the Issuer on March 21, 2024.
• The reverse stock split combined every ten shares of common stock into one, and consequently, option exercise prices were multiplied by ten while the number of shares subject to options was divided by ten.
• An option originally granted on August 3, 2023, for 85,000 shares (post-split) with a pre-amendment exercise price of $21 (post-split equivalent) was replaced with an option at an exercise price of $10.14.
• This 85,000-share option vests 25% on the six-month anniversary of August 3, 2023, and 1/36 each month thereafter, fully vesting by August 3, 2026.
• Another option originally granted on February 12, 2024, for 35,000 shares (post-split) with a pre-amendment exercise price of $19.9 (post-split equivalent) was also replaced with an option at an exercise price of $10.14.
• This 35,000-share option vests 25% on the first anniversary of February 12, 2024, and 1/48 each month thereafter, fully vesting by February 12, 2028.
• Both replacement options have an expiration date of August 2, 2033, and February 11, 2034, respectively, and require continuous service for vesting.

Sentiment

Score: 7

Explanation: The repricing of stock options to a lower exercise price is a clear positive for the executive, increasing the value of their compensation. While the underlying reverse split might suggest challenges, the specific action reported in this Form 4 is beneficial for the insider.

Positives

• The Chief Financial Officer's stock options were repriced to a significantly lower exercise price ($10.14) compared to the post-reverse split equivalent of their original exercise prices ($21 and $19.9), making them more valuable and providing a stronger incentive.
• The repricing of options can serve as a positive incentive for executive retention and alignment with shareholder interests, especially after a reverse stock split.

Negatives

• The occurrence of a reverse stock split (1-for-10) often indicates a low share price, which can be perceived negatively by the market, though the filing itself does not provide context for the split's necessity.

Future Outlook

The document details future vesting schedules for the repriced stock options, with the 85,000-share option fully vesting by August 3, 2026, and the 35,000-share option fully vesting by February 12, 2028, contingent on the Reporting Person's continuous service.

Industry Context

This filing is a standard insider transaction report (Form 4) detailing executive compensation adjustments following a corporate action (reverse stock split). Such repricings are common in the biotechnology sector, particularly for companies undergoing significant corporate restructuring or facing share price challenges, as a means to re-incentivize management.

Corporate Governance

Stakeholder Impact

• **Shareholders:** The repricing of options could be viewed as a cost to shareholders if the company's stock price does not recover sufficiently, but it also serves to incentivize key management. The reverse stock split impacts all shareholders by reducing the number of outstanding shares and increasing the per-share price.
• **Employees (specifically CFO):** The Chief Financial Officer directly benefits from the repriced options, which enhance the potential value of her equity compensation and serve as a retention incentive.

Next Steps

• Continued vesting of the 85,000-share option, with full vesting by August 3, 2026, subject to continuous service.
• Continued vesting of the 35,000-share option, with full vesting by February 12, 2028, subject to continuous service.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, SEC Form 4, Stock Option, Executive Compensation, Reverse Stock Split, Option Repricing, Chief Financial Officer, Insider Transaction